List view / Grid view
1 October 2015 | By Victoria White
Genzyme has elected to opt into the programme for development and potential future commercialisation of ALN-AT3 in territories outside of North America and Western Europe...
1 October 2015 | By Victoria White
The announcement marks the first and only FDA approval of a Regimen of two immuno-oncology agents in cancer...
1 October 2015 | By Victoria White
Secukinumab is the first interleukin-17A inhibitor to demonstrate efficacy in a Phase III study in patients with active psoriatic arthritis...
1 October 2015 | By Victoria White
Brodalumab is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signalling...
1 October 2015 | By Victoria White
The company has opened a Scientific Office in Saudi Arabia and has appointed Dr Fahad Al Showaier as Scientific Office Manager...
30 September 2015 | By Victoria White
If approved, Translarna would be the first oral protein restoration treatment that targets the underlying cause of nonsense mutation cystic fibrosis...
30 September 2015 | By Victoria White
Pregnant women who received the anti-HIV drug in their third trimester gave birth to babies whose bone mineral content was 12% lower than that of infants who were not exposed to the drug...
30 September 2015 | By Coulter Partners
Global Life Sciences search specialist, Coulter Partners is pleased to announce the appointments of Anne-Monika Dürk as Executive Vice President, Thomas Pilz as Research Associate and Ronja Lindenberg as Executive Assistant in their new Frankfurt offices....
CPhI Worldwide, organised by UBM EMEA, today announced the findings of Part II of its 2015 annual report, entitled, ‘Quality, metrics and continuous processing’, ahead of CPhI Worldwide 2015 in Madrid.
30 September 2015 | By Victoria White
The results confirm that Ofev has a long-term effect on slowing IPF disease progression and has a manageable side effect profile...
30 September 2015 | By Victoria White
Astellas has obtained worldwide rights to commercialise Chromocell's lead compound, CC8464 - an oral, peripherally-acting inhibitor of NaV1.7...
29 September 2015 | By Victoria White
This first operation is a major milestone in the London Project to Cure Blindness, which was established 10 years ago with the aim of curing vision loss in patients with wet AMD...
29 September 2015 | By Victoria White
Infants received a significant bolus of all anti-RSV antibodies via transplacental transfer. As such, the RSV F Vaccine demonstrates the potential to protect infants when they are most at risk of infection...
29 September 2015 | By Victoria White
The Oncoptye DX test could prevent patients from the side effects of unnecessary chemotherapy treatment, and save NHS England up to £5 million per year...
29 September 2015 | By Victoria White
Advanced targeted therapies now account for 60% of the drugs under development for colorectal cancer...
